Pevifoscorvir-sodium, Publications A Phase 1 study of the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium), a novel Class E capsid assembly modulator, in healthy participants
Pevifoscorvir-sodium, Publications Oral Once-Daily 300 mg ALG-000184, a Novel Capsid Assembly Modulator Demonstrates potent suppression of HBV DNA in Treatment-Naive or Currently-not-treated Subjects with Chronic HBV
Pevifoscorvir-sodium, Publications Capsid Assembly Modulator ALG-001075 Binds and Directly Targets HBeAg
Pevifoscorvir-sodium, Publications Capsid Assembly Modulator ALG-001075 Prevents cccDNA Formation and HBV DNA Integration In Vitro
Pevifoscorvir-sodium, Publications Sustained Reduction of HBV Antigen Levels During the 8-Week Follow-up Period in Treatment Naïve (TN) or Currently-Not-Treated (CNT) HBeAg-Positive Subjects with Chronic Hepatitis B Virus Infection After 96-Week 300 mg ALG-000184
Pevifoscorvir-sodium, Publications The CAM-E ALG-001075 potently reduces HBV cccDNA in preclinical experiments
Pevifoscorvir-sodium, Publications European Association for the Study of the Liver Congress (EASL) 2025 Satellite Symposium Recording
Pevifoscorvir-sodium, Publications Viral kinetics and sequence analysis of a phase I monotherapy study in subjects with chronic hepatitis B reveals a high barrier of resistance to the capsid assembly modulator ALG-000184
Pevifoscorvir-sodium, Publications The Safety and Antiviral Effect of Oral Daily 300 mg ALG-000184 in Combination with Entecavir for up to 96 Weeks in Untreated HBeAg-Positive Subjects with Chronic Hepatitis B Virus Infection